Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
Terminated
Stanford University
Phase 2
2005-11-01
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease
abnormal breast duct cytology in women with a high inherited breast cancer risk.
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis
Terminated
Autoimmunity Centers of Excellence
Phase 2
2007-11-06
Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a major health
problem. The purpose of this study is to determine the safety and effectiveness of lovastatin
for controlling inflammation in mildly active RA.
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis
Terminated
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
2007-11-06
Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a major health
problem. The purpose of this study is to determine the safety and effectiveness of lovastatin
for controlling inflammation in mildly active RA.
Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
Terminated
University of Iowa
Phase 1/Phase 2
2001-06-01
The purpose of this study is to test the safety and effectiveness of combining a drug known
as Lovastatin to the chemotherapy drug cytarabine. Lovastatin is currently used to lower
blood cholesterol levels and lab data suggests that it increases the anti-leukemia activity
of cytarabine. This research is being done because high doses of cytarabine induce remissions
in only about 25% of patients with acute myeloid leukemia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
